Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Mauer, Michael ^a   Glynn, Emily ^b   Svarstad, Einar ^c,d   Tøndel, Camilla ^c,d   Gubler, Marie Claire ^e   West, Michael ^f   Sokolovskiy, Alexey ^b   Whitley, Chester ^a   Najafian, Behzad ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CELL DAMAGE; CELL DENSITY; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; ELECTRON MICROSCOPY; FABRY DISEASE; FEMALE; GENE; GLA GENE; GLOMERULUS; HUMAN; KIDNEY BIOPSY; MALE; MOSAICISM; PHENOTYPE; PODOCYTE; X CHROMOSOME INACTIVATION; ADOLESCENT; COMPLICATION; DISEASE COURSE; GLOMERULUS FILTRATION RATE; KIDNEY; MIDDLE AGED; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MIDDLE AGED; MOSAICISM; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84911424960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112188     Document Type: Article

References (38)

1. Zarate YA, Hopkin RJ (2008) Fabry's disease. Lancet 372: 1427-1435.
2. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, et al. (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93: 112-128.
3. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775.
4. Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, et al. (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 95: 30-38.
5. Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9: 34-45.
6. Gibas AL, Klatt R, Johnson J, Clarke JT, Katz J (2008) Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease. J Genet Couns 17: 528-537.
7. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, et al. (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43: 347-352.
8. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, et al. (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34: 236-242.
9. Reiser J, Sever S (2013) Podocyte biology and pathogenesis of kidney disease. Annu Rev Med 64: 357-366.
10. Najafian B, Svarstad E, Bostad L, Gubler MC, Tondel C, et al. (2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int 79: 663-670.
11. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946.
12. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, et al. (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18: 1547-1557.
13. Kriz W, LeHir M (2005) Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 67: 404-419.
14. Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, et al. (2011) Podocyte injury damages other podocytes. J Am Soc Nephrol 22: 1275-1285.
15. Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, et al. (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24: 137-148.
16. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, et al. (2013) Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28: 505-517.
17. Najafian B, Mauer M, Hopkin RJ, Svarstad E (2013) Renal complications of Fabry disease in children. Pediatr Nephrol 28: 679-687.
18. Warnock DG, Mauer M (2014) Fabry Disease: Dose Matters. J Am Soc Nephrol.
19. Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV (2013) The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304: F333-347.
20. Najafian B, Mauer M (2011) Quantitating glomerular endothelial fenestration: an unbiased stereological approach. Am J Nephrol 33 Suppl 1: 34-39.
21. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M (2007) Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56: 2155-2160.
22. Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, et al. (2008) Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 74: 1568-1576.
23. Topham PS, Haydar SA, Kuphal R, Lightfoot JD, Salant DJ (1999) Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 55: 1763-1775.
24. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, et al. (1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13: 223-235.
25. Valbuena C, Carvalho E, Bustorff M, Ganhao M, Relvas S, et al. (2008) Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch 453: 329-338.
26. Wolf G, Chen S, Ziyadeh FN (2005) From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634.
27. Pinto LL, Vieira TA, Giugliani R, Schwartz IV (2010) Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J - Rare Dis 5: 14.
28. Migeon BR (2006) The role of X inactivation and cellular mosaicism in women's health and sex-specific diseases. JAMA 295: 1428-1433.
29. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105: 2812-2817.
30. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, et al. (2004) The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65: 299-307.
31. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, et al. (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl) 83: 647-654.
32. Elstein D, Schachamorov E, Beeri R, Altarescu G (2012) X-inactivation in Fabry disease. Gene 505: 266-268.
33. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, et al. (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27: 1042-1049.
34. - (2013) The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff.
35. Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, et al. (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48: 227-235.
36. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, et al. (1997) Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3: 174-182.
37. Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, et al. (2005) Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 101: c33-38.
38. Wang C, Wang Y, Zhu F, Xiong J (2013) A Missense Mutation of the alpha- Galactosidase A Gene in a Chinese Family of Fabry Disease with Renal Failure. Kidney Blood Press Res 37: 221-228.